Mirtazapine Compared With Paroxetine in Major Depression
J Clin Psychiatry 2000;61(9):656-663
© Copyright 2017 Physicians Postgraduate Press, Inc.
Purchase This PDF for $40.00
If you are not a paid subscriber, you may purchase the PDF.
(You'll need the free Adobe Acrobat Reader.)
Receive immediate full-text access to JCP. You can subscribe to JCP online-only ($86) or print + online ($156 individual).
With your subscription, receive a free PDF collection of the NCDEU Festschrift articles. Hurry! This offer ends December 31, 2011.
If you are a paid subscriber to JCP and do not yet have a username and password, activate your subscription now.
As a paid subscriber who has activated your subscription, you have access to the HTML and PDF versions of this item.
Click here to login.
Did you forget your password?
Still can't log in? Contact the Circulation Department at 1-800-489-1001 x4 or send email
Background: The aim was to compare the efficacy
and tolerability of mirtazapine with those of paroxetine.
Method: 275 outpatients with a diagnosis of
major depressive episode (DSM-IV) and a score >= 18 on the
17-item Hamilton Rating Scale for Depression (HAM-D-17) were
randomly assigned to 6 weeks of treatment with mirtazapine (15-45
mg/day) or paroxetine (20-40 mg/day). Efficacy was assessed by
the HAM-D-17, Hamilton Rating Scale for Anxiety (HAM-A), and
Clinical Global Impressions scales (Severity and Improvement),
and analyses were performed on the intent-to-treat sample (127
mirtazapine-treated patients and 123 paroxetine-treated
Results: Mean daily doses were 32.7 mg of
mirtazapine and 22.9 mg of paroxetine. Thirty patients in the
mirtazapine group and 33 in the paroxetine group dropped out.
Both drugs were equally effective in reducing symptoms of
depression. At week 1, the mean HAM-D-17 total score was
significantly lower in mirtazapine- than paroxetine-treated
patients (16.5 vs. 18.8, p = .0032). Similarly, significantly
more mirtazapine-treated patients were HAM-D-17 responders (>=
50% decrease from baseline) at weeks 1 (23.2% vs. 8.9%, p = .002)
and 4 (58.3% vs. 44.5%, p = .04). Both treatments were equally
effective in reducing anxiety. However, the reduction in mean
HAM-A total score was significantly greater with mirtazapine than
with paroxetine at week 1 (-5.1 vs. -3.5, p = .0435).
Tolerability of both treatments was good, with more nausea,
vomiting, tremor, and sweating in the paroxetine group and more
weight increase and influenza-like symptoms in the mirtazapine
Conclusion: Mirtazapine and paroxetine
were equally effective after 6 weeks of therapy and were both
well tolerated. A potentially faster onset of overall therapeutic
efficacy of mirtazapine was suggested by significant differences
between treatments after 1 week of therapy that were due to
slightly larger improvements of several core symptoms of
depression as well as distinct prevention of treatment-emergent
worsening of anxiety and physical components of depression.